Provided herein are small molecule inhibitors of Polycomb Repressive Complex 1 (PRC1) activity, and methods of use thereof for the treatment of disease, including leukemia and other cancers, as well as other diseases dependent on the activity of PRC1.

Compounds represented by the following formula (I):

##STR00001##

wherein each symbol in the formula is as described herein, or a salt thereof, and compositions comprising the same, and methods of using the same as an NRF2 activator and/or a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.

Compounds represented by the following formula (I):

##STR00001##

wherein each symbol in the formula is as described herein, or a salt thereof, and compositions comprising the same, and methods of using the same as an NRF2 activator and/or a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.

A compound of Formula (I) is provided:

##STR00001##

where the variables are defined herein.

A compound of Formula (I) is provided:

##STR00001##

where the variables are defined herein.

A light-emitting device includes a heterocyclic compound represented by Formula 1:

##STR00001##

The heterocyclic compound represented by Formula 1 may have a high glass transition temperature (T.sub.g) and/or melting point for excellent thermal resistance, and excellent hole injectability and/or transportability. Accordingly, the light-emitting device may have excellent luminance, luminescence efficiency, lifespan, and/or driving voltage.

Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic device.

##STR00001##

Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic device.

##STR00001##

The present invention relates to compounds suitable for use in electronic devices, and to electronic devices, especially organic electroluminescent devices, comprising these compounds.

The present invention relates to compounds suitable for use in electronic devices, and to electronic devices, especially organic electroluminescent devices, comprising these compounds.